The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

An Overview of a Trial Exploring MEK162 in Advanced Biliary Cancer

Ghassan K. Abou-Alfa, MD
Published Online:1:44 PM, Wed April 26, 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.